Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.

ABSTRACT:

Background

Glioma is a primary malignancy of the central nervous system (CNS). As biomedicine advances, an efficient molecular target is urgently needed for the diagnosis and treatment of glioma. Meanwhile, several studies have demonstrated that glioma development is closely related to immunity. PARP9 is an inactive mono-ADP-ribosyltransferase belonging to the poly-ADP ribosyltransferase (ARTD) family. In this article, we aimed to reveal the relationship between PARP9 and glioma and explore the potential prognostic value and immunotherapeutic targetability of PARP9 in glioma.

Methods

PARP9 transcript levels were analyzed with TCGA and GEO databases. The clinicopathological information of patients with glioma in the TCGA database and gene expression profiles were analyzed to

SUBMITTER: Xu H 

PROVIDER: S-EPMC7366751 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature